The global immunoglobulin market size was estimated to be US$ 12.5 billion in 2021 and is expected to grow at a CAGR of 7% between 2023 to 2032.
Immunoglobulins are characterized as a type of glycoprotein molecules that are produced by white blood cells (WBCs) or plasma. They are also known as antibodies that identify antigens such as bacteria and viruses by binding to them and also neutralizing them. In many people, immunoglobulins need to be administered via different routes for the body to neutralize pathogens and to maintain immunity.
The property of Immunoglobulins to correctly identify and bind to antigens also helps in diagnosis of multiple diseases such as immune deficiencies, allergies and auto immune diseases namely celiac disease, lupus and arthritis. Based on biological structure, target specificity, distribution and characteristics different immunoglobulins are classified accordingly.
There is a great demand for immunoglobulins for treatment and diagnostic purposes due to increased awareness and greater efficiency. Its proven efficiency in treating rare immunodeficiency disorders like chronic inflammatory demyelinating polyneuropathy (CIDP) is bolstering the market growth.
The rising number of patients suffering from autoimmune diseases such as multiple myeloma, Waldenstrom macroglobulinemia, hypogammaglobulinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) will drive market growth
In many developed countries the population of people over 60 years in steadily increasing. As the persons age increases the incidences of autoimmune and chronic diseases also increase.
As more and more people are consuming fast foods as a result of increased urbanization, stressful and sedentary lifestyles this market is predicted to grow.
The number of research and development activities for autoimmune disorders has increased and there is an increase in investment for developing new and advanced technologies that will bolster this market growth during the forecast period.
The global pandemic of COVID-19 has offered pharmaceutical companies numerous opportunities to increase their research and development budgets in order to offer treatment options to critically ill COVID-19 patients. Immunoglobulin therapy for COVID-19 infection has shown to be favorable in treating COVID-19. Also, the increase of activities by the regulatory authorities to approve new treatments has further bolstered this market growth.
Developing immunoglobulins is a highly complex and costly process that requires significant investments, clinical trial expertise, quality systems, scientific standards and technical capabilities. Immunoglobulin manufacturers are required to invest in clinical trials and post-approval safety monitoring programs due to stringent regulations required by the regulators.
There is a shortage of skilled healthcare professionals and also lack of training to administer immunoglobulin therapies. Also, there are few apprehensions about the safety of this therapy among the healthcare community. Therefore, the lack of awareness and skills could be restraining factors for market growth.
Immunoglobulin Market Share Analysis, by Geography (2022)
The major players operating in the immunoglobulins market are Baxter, Biotest AG, China Biologic Products Holdings Inc, CSL Limited, Grifols S.A., Kedrion S.p.A, Octapharma, GREEN CROSS CORP, Coram LLC, Momenta Pharmaceuticals, Option Care Enterprises Inc, ADMA Biologics Inc, Gentian Diagnostics AS, Mabtech, Mitra & Co. Pvt. Ltd, Cygnus Technologies, Kamada Pharmaceuticals, HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD, Kedrion Biopharma Inc, Hualan Biological Engineering Inc and others.
By Product
By Application
By Mode of Delivery
By Geography
The global immunoglobulin market size was estimated to be US$ 12.5 billion in 2021.
Global Immunoglobulin market is expected to achieve CAGR of 7% from 2023 to 2032.
Immunoglobulins are characterized as a type of glycoprotein molecules that are produced by white blood cells (WBCs) or plasma. They are also known as antibodies that identify antigens such as bacteria and viruses by binding to them and also neutralizing them.
Rise in the incidences of autoimmune and chronic diseases and prevalence of sedentary lifestyle are driving the growth of Immunoglobulin market.
Prominent active players of Immunoglobulin market include but are not limited to Biotest AG., China Biologic Products Holdings, Inc., CSL Limited, Grifols, S.A and. Kedrion S.p.A.
Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies are the applications of Immunoglobulin.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved